Randal Jacks, MD
Family Medicine · New Braunfels, TXNPI 1356314124
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,351 of the $6,094 with a category attached, or 87.8%. It is spread thinly across 27 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,296 and has fallen 87.4% since, to $415 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $45.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$982
- Amgen$902
- Amarin Pharma, Inc.$490
- AbbVie$459
- Medtronic$425
- Teva Pharmaceuticals USA, Inc.$382
- plus $2K from 21 others
Across 141 payments — averaging $3023.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$303K
- AbbVie$106K
- Novartis$13K
- Boehringer Ingelheim$4K
What the payments were for
- Travel & lodging$73712%
- Food & beverage$5,35188%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $982 |
| Amgen | 13 | $902 |
| Amarin Pharma, Inc. | 12 | $490 |
| AbbVie(2 entities) | 9 | $459 |
| Medtronic | 5 | $425 |
| Teva Pharmaceuticals USA, Inc. | 3 | $382 |
| AstraZeneca | 12 | $366 |
| Lilly USA, LLC | 15 | $361 |
| Abbott | 3 | $286 |
| Johnson & Johnson | 11 | $274 |
| Novo Nordisk | 11 | $225 |
| Boehringer Ingelheim | 3 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $118 |
| Biohaven Pharmaceuticals, Inc. | 1 | $117 |
| Merck | 2 | $110 |
| Surmodics, Inc. | 1 | $73 |
| Novartis | 4 | $69 |
| GSK | 4 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Genentech USA, Inc. | 3 | $46 |
| Antares Pharma, Inc. | 3 | $44 |
| Radius Health, Inc. | 2 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,094 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $82,665 |
| EliquisApixaban | 66 | $48,196 |
| JardianceEmpagliflozin | 50 | $39,364 |
| MounjaroTirzepatide | 25 | $29,145 |
| TrulicityDulaglutide | 20 | $24,621 |
| ProliaDenosumab | 14 | $23,189 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $20,386 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $11,366 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $7,012 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $6,960 |
| SynthroidLevothyroxine Sodium | 70 | $4,929 |
| BelsomraSuvorexant | 11 | $4,577 |
| Atorvastatin Calcium | 426 | $3,446 |
| Levothyroxine Sodium | 291 | $2,987 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $225 | $82,66584 claims |
| Lilly USA, LLCMounjaro, Trulicity | $361 | $53,76745 claims |
| PfizerEliquis | $11 | $48,19666 claims |
| Boehringer IngelheimJardiance | $134 | $39,36450 claims |
| AmgenProlia | $902 | $23,18914 claims |
| MerckJanumet, Belsomra | $110 | $15,94325 claims |
| AbbVieSynthroid | $459 | $4,92970 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in New Braunfels
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.